Introduction
Lung cancer remains a leading cause of cancer-related deaths worldwide. As tumors grow, they require an increasing supply of oxygen and nutrients, which they obtain by triggering angiogenesis—the formation of new blood vessels from existing ones. The primary driver of this process is the Vascular Endothelial Growth Factor (VEGF) and its receptor, VEGFR2. While several anti-angiogenic therapies exist, researchers are increasingly looking toward "drug repurposing"—finding new uses for existing, safe medications.
This study explores the potential of Azithromycin, a widely used FDA-approved antibiotic, as a novel inhibitor of tumor angiogenesis in lung cancer.
Targeting the Tumor Infrastructure
A key finding of this research is that Azithromycin specifically targets the cells that build blood vessels, known as Human Lung Tumor-associated Endothelial Cells (HLT-ECs). Interestingly, the drug was found to be significantly more potent against these endothelial cells than against the lung cancer cells themselves.
By suppressing the activation (phosphorylation) of the VEGFR2 receptor, Azithromycin disrupts critical downstream signaling pathways, including PI3K/Akt and Focal Adhesion Kinase (FAK). This molecular interference prevents endothelial cells from adhering, proliferating, and organizing into the complex tube-like structures necessary for functional blood vessels.
Experimental Evidence
The researchers validated Azithromycin's efficacy through both in vitro and in vivo models. In laboratory cultures, the drug inhibited the formation of capillary networks in a dose-dependent manner. This was further confirmed using a directed in vivo angiogenesis assay (DIVAA), where Azithromycin significantly reduced the recruitment of new vessels into implanted angioreactors in mice.
In lung tumor xenograft models, daily treatment with Azithromycin led to a marked reduction in tumor volume. Histological analysis of these tumors revealed a dramatic decrease in microvessel density, confirming that the drug's anti-tumor effect is primarily driven by its ability to "starve" the tumor of its blood supply.
Key Insights
- Selective Vulnerability: HLT-ECs are more susceptible to Azithromycin-induced apoptosis than various lung cancer cell lines (e.g., A549, PC-9), suggesting a favorable therapeutic window.
- Cytoskeletal Disruption: The drug interferes with the assembly of actin stress fibers and focal adhesions, which are essential for the structural integrity and movement of endothelial cells.
- Potency: The inhibitory effect on tube formation was observed at clinically relevant concentrations, with an IC50 of approximately 3 µM.
Conclusion and Future Directions
The study identifies Azithromycin as a promising candidate for repurposing in lung cancer therapy. By targeting the VEGFR2-mediated signaling pathways in the tumor microenvironment, it offers a dual benefit: inhibiting the growth of new vessels and inducing death in existing tumor-associated endothelial cells.
While these results are compelling, further research is needed to optimize dosing schedules and determine if Azithromycin can enhance the efficacy of current standard-of-care chemotherapies or immunotherapies in clinical settings.
Summary updated